Quality of life and cancer-related needs in patients with choroidal melanoma.
|Title||Quality of life and cancer-related needs in patients with choroidal melanoma.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Wiley JF, Laird K, Beran T, McCannel TA, Stanton AL|
|Journal||Br J Ophthalmol|
|Date Published||2013 Nov|
|Keywords||Adult, Aged, Aged, 80 and over, Choroid Neoplasms, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Incidence, Los Angeles, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Quality of Life, Surveys and Questionnaires, Survival Rate, Treatment Outcome, Visual Acuity, Young Adult|
AIMS: To assess quality of life (QoL) indices and their associations with treatment modality, sociodemographics and cancer-related needs in choroidal melanoma patients.
METHODS: Patients (N=99) treated at the University of California, Los Angeles, for choroidal melanoma within the prior 5 years (M=2.05) completed questionnaires assessing demographics, cancer-related needs, vision-specific QoL, depressive symptoms and concern about recurrence. Visual acuity, comorbidities, treatment modality (radiotherapy, enucleation) and years since diagnosis were gathered from medical records. Primary analyses were multiple regressions.
RESULTS: Although concern about cancer recurrence was elevated, QoL was better than in other oncology samples and comparable with healthy samples on some outcomes. Enucleation was associated with worse vision-specific QoL, and presence of comorbid diseases was associated with worse vision-specific QoL, depressive symptoms and concern about cancer recurring (all p values<0.05). Patients who experienced at least one stressful life event in the past year (vs no events) reported more depressive symptoms (p<0.01). Report of more unmet cancer needs was associated with worse vision-specific QoL, depressive symptoms and more concern about recurrence (all p values<0.05), uniquely explaining 4%-12% of the variance.
CONCLUSIONS: For choroidal melanoma patients, an average of 2 years after treatment, the number of physical comorbidities and unmet cancer needs were the strongest correlates of poorer QoL.
|Alternate Journal||Br J Ophthalmol|
|PubMed Central ID||PMC3838665|
|Grant List||T32 GM084903 / GM / NIGMS NIH HHS / United States |
T32GM084903 / GM / NIGMS NIH HHS / United States